Combination trials gather momentum
Viralytics is escalating combination trials of its Cavatak oncolytic virotherapy with immune checkpoint inhibitors (ICI), adding a collaboration with Merck (N:MRK) to study IV Cavatak combined with Keytruda in advanced lung and bladder cancers to its portfolio of ongoing trials combining intralesional Cavatak with Keytruda or Yervoy in melanoma patients. Cavatak has the potential to markedly improve the proportion of patients who respond to ICI therapy and we expect it to continue to attract attention from big pharma. We value Viralytics at A$192m or A$1.04 per share.
Viralytics and Merck collaborate on combination trial
Viralytics and Merck will collaborate on a clinical trial combining intravenous (IV) Cavatak with Merck’s marketed anti-PD1 checkpoint inhibitor Keytruda (pembrolizumab) in lung and bladder cancer. The Phase Ib trial, which we expect to begin in H116, will be the second stage of Viralytics’ ongoing STORM trial.
To Read the Entire Report Please Click on the pdf File Below